{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T17:19:54Z","timestamp":1790356794108,"version":"4.1.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,7,16]],"date-time":"2024-07-16T00:00:00Z","timestamp":1721088000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,16]],"date-time":"2024-07-16T00:00:00Z","timestamp":1721088000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Respir Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Morphine relieves dyspnea in various clinical circumstances. Whether or not this applies to patients admitted to intensive care units (ICUs) for acute respiratory failure (ARF) is unknown. We evaluated the efficacy and safety of low-dose morphine on dyspnea in patients admitted to the ICU for ARF.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In this single-center, double-blind, phase 2, randomized, controlled trial, we assigned non-intubated adults admitted to the ICU for ARF with severe dyspnea, defined by a visual analog scale for dyspnea (dyspnea-VAS) from zero (no dyspnea) to 100 mm (worst imaginable dyspnea) \u226540 mm, to receive a low dose of Morphine Hydrochloride (intravenous titration followed by subcutaneous relay) or Placebo. All patients received standard therapy, including etiological treatment and non-invasive respiratory support.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Twenty-two patients were randomized, 11 in each group. The average dyspnea (median [interquartile range]) over 24 hours\u00a0did not significantly differ between the two groups (40 [25\u00a0\u2013 43] mm in the Morphine group vs. 40 [36\u00a0\u2013 49] mm in the Placebo group, <jats:italic>p<\/jats:italic>=0.411). Dyspnea-VAS was lower in the Morphine group than in the Placebo group at the end of intravenous titration (30 [11 \u2013 30] vs. 35 [30 \u2013 44], <jats:italic>p<\/jats:italic>=0.044) and four hours later (18 [10 \u2013 29] vs. 50 [30 \u2013 60], <jats:italic>p<\/jats:italic>=0.043). The cumulative probability of intubation was higher in the Morphine group than in the Placebo group (<jats:italic>p<\/jats:italic>=0.046)<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>In this phase 2 pilot trial, morphine did not improve 24-hour average dyspnea in adult patients with ARF, even though it had a statistically significant immediate effect. Of concern, Morphine use was associated with a higher intubation rate.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>The protocol was declared on the ClinicalTrial.gov database (no. NCT04358133) and was published in September 2022.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12931-024-02867-2","type":"journal-article","created":{"date-parts":[[2024,7,16]],"date-time":"2024-07-16T10:03:48Z","timestamp":1721124228000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Low dose of morphine to relieve dyspnea in acute respiratory failure: the OpiDys double-blind randomized controlled trial"],"prefix":"10.1186","volume":"25","author":[{"given":"Robin","family":"Deleris","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00f4me","family":"Bureau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sa\u00efd","family":"Lebbah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxens","family":"Decav\u00e8le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Dres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Mayaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Similowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agn\u00e8s","family":"Dechartres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Demoule","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,16]]},"reference":[{"key":"2867_CR1","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s00134-023-07246-x","volume":"50","author":"A Demoule","year":"2024","unstructured":"Demoule A, Decavele M, Antonelli M, Camporota L, Abroug F, Adler D, et al. Dyspnoea in acutely ill mechanically ventilated adult patients: an ERS\/ESICM statement. Intensive Care Med. 2024;50:159\u201380.","journal-title":"Intensive Care Med."},{"key":"2867_CR2","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1056\/NEJMoa1503326","volume":"372","author":"J-P Frat","year":"2015","unstructured":"Frat J-P, Thille AW, Mercat A, Girault C, Ragot S, Perbet S, et al. High-Flow Oxygen through Nasal Cannula in Acute Hypoxemic Respiratory Failure. N Engl J Med. 2015;372:2185\u201396.","journal-title":"N Engl J Med."},{"key":"2867_CR3","doi-asserted-by":"publisher","first-page":"1702637","DOI":"10.1183\/13993003.02637-2017","volume":"52","author":"L Dangers","year":"2018","unstructured":"Dangers L, Montlahuc C, Kouatchet A, Jaber S, Meziani F, Perbet S, et al. Dyspnoea in patients receiving noninvasive ventilation for acute respiratory failure: prevalence, risk factors and prognostic impact: A prospective observational study. Eur Respir J. 2018;52:1702637.","journal-title":"Eur Respir J."},{"key":"2867_CR4","doi-asserted-by":"publisher","first-page":"00418","DOI":"10.1183\/23120541.00418-2021","volume":"7","author":"LS Menga","year":"2021","unstructured":"Menga LS, Grieco DL, Ros\u00e0 T, Cesarano M, Delle Cese L, Berardi C, et al. Dyspnoea and clinical outcome in critically ill patients receiving noninvasive support for COVID-19 respiratory failure: post hoc analysis of a randomised clinical trial. ERJ Open Res. 2021;7:00418\u20132021.","journal-title":"ERJ Open Res."},{"key":"2867_CR5","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1164\/rccm.202108-1857OC","volume":"205","author":"A Demoule","year":"2022","unstructured":"Demoule A, Hajage D, Messika J, Jaber S, Diallo H, Coutrot M, et al. Prevalence, Intensity, and Clinical Impact of Dyspnea in Critically Ill Patients Receiving Invasive Ventilation. Am J Respir Crit Care Med. 2022;205:917\u201326.","journal-title":"Am J Respir Crit Care Med."},{"key":"2867_CR6","doi-asserted-by":"crossref","unstructured":"S de M, F P, M C, B M, A C, N B, et al. Postintensive care unit psychological burden in patients with chronic obstructive pulmonary disease and informal caregivers: A multicenter study. Crit Care Med. 2011 [cited 2023 May 30];39. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/21037472\/","DOI":"10.1097\/CCM.0b013e3181feb824"},{"key":"2867_CR7","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1164\/rccm.201812-2248ED","volume":"199","author":"A Demoule","year":"2019","unstructured":"Demoule A, Similowski T. Respiratory Suffering in the ICU: Time for Our Next Great Cause. Am J Respir Crit Care Med. 2019;199:1302\u20134.","journal-title":"Am J Respir Crit Care Med."},{"key":"2867_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00134-013-3117-3","volume":"40","author":"M Schmidt","year":"2014","unstructured":"Schmidt M, Banzett RB, Raux M, Mor\u00e9lot-Panzini C, Dangers L, Similowski T, et al. Unrecognized suffering in the ICU: addressing dyspnea in mechanically ventilated patients. Intensive Care Med. 2014;40:1\u201310.","journal-title":"Intensive Care Med."},{"key":"2867_CR9","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1097\/SPC.0000000000000098","volume":"8","author":"JM L\u00f3pez-Saca","year":"2014","unstructured":"L\u00f3pez-Saca JM, Centeno C. Opioids prescription for symptoms relief and the impact on respiratory function: updated evidence. Curr Opin Support Palliat Care. 2014;8:383\u201390.","journal-title":"Curr Opin Support Palliat Care."},{"key":"2867_CR10","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1513\/AnnalsATS.201611-922CC","volume":"14","author":"MI Soffler","year":"2017","unstructured":"Soffler MI, Rose A, Hayes MM, Banzett R, Schwartzstein RM. Treatment of Acute Dyspnea with Morphine to Avert Respiratory Failure. Ann Am Thorac Soc. 2017;14:584\u20138.","journal-title":"Ann Am Thorac Soc."},{"key":"2867_CR11","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1136\/thorax.57.11.939","volume":"57","author":"A-L Jennings","year":"2002","unstructured":"Jennings A-L, Davies AN, Higgins JPT, Gibbs JSR, Broadley KE. A systematic review of the use of opioids in the management of dyspnoea. Thorax. 2002;57:939\u201344.","journal-title":"Thorax."},{"key":"2867_CR12","doi-asserted-by":"crossref","unstructured":"Ekstr\u00f6m M, Nilsson F, Abernethy AA, Currow DC. Effects of opioids on breathlessness and exercise capacity in chronic obstructive pulmonary disease. A systematic review. Ann Am Thorac Soc. 2015;12:1079\u201392.","DOI":"10.1513\/AnnalsATS.201501-034OC"},{"key":"2867_CR13","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1023\/A:1008337624200","volume":"10","author":"C Mazzocato","year":"1999","unstructured":"Mazzocato C, Buclin T, Rapin CH. The effects of morphine on dyspnea and ventilatory function in elderly patients with advanced cancer: a randomized double-blind controlled trial. Ann Oncol Off J Eur Soc Med Oncol. 1999;10:1511\u20134.","journal-title":"Ann Oncol Off J Eur Soc Med Oncol."},{"key":"2867_CR14","doi-asserted-by":"crossref","unstructured":"Johnson MJ, McDonagh TA, Harkness A, McKay SE, Dargie HJ. Morphine for the relief of breathlessness in patients with chronic heart failure--a pilot study. Eur J Heart Fail. 2002;4:753\u20136.","DOI":"10.1016\/S1388-9842(02)00158-7"},{"key":"2867_CR15","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1136\/heart.89.9.1085","volume":"89","author":"SG Williams","year":"2003","unstructured":"Williams SG, Wright DJ, Marshall P, Reese A, Tzeng B-H, Coats AJS, et al. Safety and potential benefits of low dose diamorphine during exercise in patients with chronic heart failure. Heart. 2003;89:1085\u20136.","journal-title":"Heart."},{"key":"2867_CR16","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1191\/0269216305pm998oa","volume":"19","author":"S Allen","year":"2005","unstructured":"Allen S, Raut S, Woollard J, Vassallo M. Low dose diamorphine reduces breathlessness without causing a fall in oxygen saturation in elderly patients with end-stage idiopathic pulmonary fibrosis. Palliat Med. 2005;19:128\u201330.","journal-title":"Palliat Med."},{"key":"2867_CR17","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1089\/jpm.2007.0131","volume":"11","author":"KE Clemens","year":"2008","unstructured":"Clemens KE, Quednau I, Klaschik E. Is there a higher risk of respiratory depression in opioid-na\u00efve palliative care patients during symptomatic therapy of dyspnea with strong opioids? J Palliat Med. 2008;11:204\u201316.","journal-title":"J Palliat Med."},{"key":"2867_CR18","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.jpainsymman.2006.09.015","volume":"33","author":"KE Clemens","year":"2007","unstructured":"Clemens KE, Klaschik E. Symptomatic therapy of dyspnea with strong opioids and its effect on ventilation in palliative care patients. J Pain Symptom Manage. 2007;33:473\u201381.","journal-title":"J Pain Symptom Manage."},{"key":"2867_CR19","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1089\/jpm.2008.0065","volume":"11","author":"MAC Pinna","year":"2008","unstructured":"Pinna MAC. Re: Is there a higher risk of respiratory depression in opioid-na\u00efve palliative care patients during symptomatic therapy of dyspnea with strong opioids? J Palliat Med. 2008;11:822.","journal-title":"J Palliat Med."},{"key":"2867_CR20","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1016\/j.jpainsymman.2011.05.007","volume":"43","author":"D Jensen","year":"2012","unstructured":"Jensen D, Alsuhail A, Viola R, Dudgeon DJ, Webb KA, O\u2019Donnell DE. Inhaled fentanyl citrate improves exercise endurance during high-intensity constant work rate cycle exercise in chronic obstructive pulmonary disease. J Pain Symptom Manage. 2012;43:706\u201319.","journal-title":"J Pain Symptom Manage."},{"key":"2867_CR21","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1177\/0269216307077328","volume":"21","author":"B Estfan","year":"2007","unstructured":"Estfan B, Mahmoud F, Shaheen P, Davis MP, Lasheen W, Rivera N, et al. Respiratory function during parenteral opioid titration for cancer pain. Palliat Med. 2007;21:81\u20136.","journal-title":"Palliat Med."},{"key":"2867_CR22","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1111\/bcp.12842","volume":"81","author":"DC Currow","year":"2016","unstructured":"Currow DC, Ekstr\u00f6m M, Johnson MJ. Opioids in chronic obstructive pulmonary disease: the whole picture using all available evidence. Br J Clin Pharmacol. 2016;81:795\u20136.","journal-title":"Br J Clin Pharmacol."},{"key":"2867_CR23","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.jpainsymman.2010.11.021","volume":"42","author":"DC Currow","year":"2011","unstructured":"Currow DC, McDonald C, Oaten S, Kenny B, Allcroft P, Frith P, et al. Once-daily opioids for chronic dyspnea: a dose increment and pharmacovigilance study. J Pain Symptom Manage. 2011;42:388\u201399.","journal-title":"J Pain Symptom Manage."},{"key":"2867_CR24","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s00134-013-3153-z","volume":"40","author":"K Puntillo","year":"2014","unstructured":"Puntillo K, Nelson JE, Weissman D, Curtis R, Weiss S, Frontera J, et al. Palliative care in the ICU: relief of pain, dyspnea, and thirst\u2014A report from the IPAL-ICU Advisory Board. Intensive Care Med. 2014;40:235\u201348.","journal-title":"Intensive Care Med."},{"key":"2867_CR25","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1001\/jamainternmed.2020.3134","volume":"180","author":"CA Verberkt","year":"2020","unstructured":"Verberkt CA, van den Beuken-van Everdingen MHJ, Schols JMGA, Hameleers N, Wouters EFM, Janssen DJA. Effect of Sustained-Release Morphine for Refractory Breathlessness in Chronic Obstructive Pulmonary Disease on Health Status: A Randomized Clinical Trial. JAMA Intern Med. 2020;180:1306\u201314.","journal-title":"JAMA Intern Med."},{"key":"2867_CR26","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1378\/chest.09-1543","volume":"137","author":"DA Mahler","year":"2010","unstructured":"Mahler DA, Selecky PA, Harrod CG, Benditt JO, Carrieri-Kohlman V, Curtis JR, et al. American College of Chest Physicians consensus statement on the management of dyspnea in patients with advanced lung or heart disease. Chest. 2010;137:674\u201391.","journal-title":"Chest."},{"key":"2867_CR27","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1186\/s13063-022-06754-3","volume":"23","author":"A Demoule","year":"2022","unstructured":"Demoule A, Deleris R, Bureau C, Lebbah S, Decav\u00e8le M, Dres M, et al. Low dose of morphine to relieve dyspnea in acute respiratory failure (OpiDys): protocol for a double-blind randomized controlled study. Trials. 2022;23:828.","journal-title":"Trials."},{"key":"2867_CR28","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1097\/00003246-200107000-00012","volume":"29","author":"EW Ely","year":"2001","unstructured":"Ely EW, Margolin R, Francis J, May L, Truman B, Dittus R, et al. Evaluation of delirium in critically ill patients: validation of the Confusion Assessment Method for the Intensive Care Unit (CAM-ICU). Crit Care Med. 2001;29:1370\u20139.","journal-title":"Crit Care Med."},{"key":"2867_CR29","unstructured":"US National Cancer Institute. Departement Of Health And Human Services. Common Terminology Criteria for Adverse Events (CTCAE). Version 5.0. Published: November 27, 2017. Available from: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.htm"},{"key":"2867_CR30","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/j.jpainsymman.2013.01.011","volume":"46","author":"MJ Johnson","year":"2013","unstructured":"Johnson MJ, Bland JM, Oxberry SG, Abernethy AP, Currow DC. Clinically important differences in the intensity of chronic refractory breathlessness. J Pain Symptom Manage. 2013;46:957\u201363.","journal-title":"J Pain Symptom Manage."},{"key":"2867_CR31","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1097\/CCM.0000000000002818","volume":"46","author":"J-P Frat","year":"2018","unstructured":"Frat J-P, Ragot S, Coudroy R, Constantin J-M, Girault C, Prat G, et al. Predictors of Intubation in Patients With Acute Hypoxemic Respiratory Failure Treated With a Noninvasive Oxygenation Strategy. Crit Care Med. 2018;46:208\u201315.","journal-title":"Crit Care Med."},{"key":"2867_CR32","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1097\/CCM.0b013e31821e8779","volume":"39","author":"M Schmidt","year":"2011","unstructured":"Schmidt M, Demoule A, Polito A, Porchet R, Aboab J, Siami S, et al. Dyspnea in mechanically ventilated critically ill patients. Crit Care Med. 2011;39:2059\u201365.","journal-title":"Crit Care Med."},{"key":"2867_CR33","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1164\/rccm.202301-0188OC","volume":"208","author":"M Decav\u00e8le","year":"2023","unstructured":"Decav\u00e8le M, Bureau C, Campion S, Nierat M-C, Rivals I, Wattiez N, et al. Interventions Relieving Dyspnea in Intubated Patients Show Responsiveness of the Mechanical Ventilation-Respiratory Distress Observation Scale. Am J Respir Crit Care Med. 2023;208:39\u201348.","journal-title":"Am J Respir Crit Care Med."},{"key":"2867_CR34","doi-asserted-by":"crossref","unstructured":"Similowski T, Serresse L. Lessons from negative dyspnoea studies: arguments for the multidimensional evaluation of multidirectional therapeutic approaches. Eur Respir J\u00a0[Internet]. 2019 [cited 2023 Aug 25];53. Available from: https:\/\/erj.ersjournals.com\/content\/53\/1\/1802471.","DOI":"10.1183\/13993003.02471-2018"},{"key":"2867_CR35","doi-asserted-by":"publisher","first-page":"1801270","DOI":"10.1183\/13993003.01270-2018","volume":"53","author":"DC Currow","year":"2019","unstructured":"Currow DC, Ekstr\u00f6m M, Louw S, Hill J, Fazekas B, Clark K, et al. Sertraline in symptomatic chronic breathlessness: a double blind, randomised trial. Eur Respir J. 2019;53:1801270.","journal-title":"Eur Respir J."},{"key":"2867_CR36","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.pupt.2016.06.007","volume":"39","author":"L Dangers","year":"2016","unstructured":"Dangers L, Laviolette L, Charbit B, Similowski T, Mor\u00e9lot-Panzini C. Nefopam, a non-opioid analgesic, does not alleviate experimental work\/effort dyspnoea in healthy humans: A randomised controlled trial. Pulm Pharmacol Ther. 2016;39:74\u201380.","journal-title":"Pulm Pharmacol Ther."},{"key":"2867_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/j.pain.0000000000001367","volume":"160","author":"G Ongaro","year":"2019","unstructured":"Ongaro G, Kaptchuk TJ. Symptom perception, placebo effects, and the Bayesian brain. Pain. 2019;160:1\u20134.","journal-title":"Pain."},{"key":"2867_CR38","doi-asserted-by":"publisher","first-page":"1802316","DOI":"10.1183\/13993003.02316-2018","volume":"53","author":"DC Currow","year":"2019","unstructured":"Currow DC, Agar M, Ekstr\u00f6m M. Sertraline or placebo in chronic breathlessness? Lessons from placebo research. Eur Respir J. 2019;53:1802316.","journal-title":"Eur Respir J."},{"key":"2867_CR39","doi-asserted-by":"crossref","unstructured":"Marciniuk D, Goodridge D, Hernandez P, Rocker G, Balter M, Bailey P, et al. Managing dyspnea in patients with advanced chronic obstructive pulmonary disease: a Canadian Thoracic Society clinical practice guideline. Can Respir J. 2011;18(2):69\u201378.","DOI":"10.1155\/2011\/745047"},{"key":"2867_CR40","doi-asserted-by":"crossref","unstructured":"Parshall M, Schwartzstein R, Adams L, Banzett R, Manning H, Bourveau J, et al. An official American Thoracic Society statement: update on the mechanisms, assessment, and management of dyspnea. Am J Respir Crit Care Med. 2012;185(4):435\u201352.","DOI":"10.1164\/rccm.201111-2042ST"},{"key":"2867_CR41","doi-asserted-by":"crossref","unstructured":"Mazzocato C, Buclin T, Rapin CH. The effects of morphine on dyspnea and ventilatory function in elderly patients with advanced cancer: a randomized double-blind controlled trial. Ann Oncol Off J Eur Soc Med Oncol. 1999;10:1511\u20134.","DOI":"10.1023\/A:1008337624200"},{"key":"2867_CR42","doi-asserted-by":"crossref","unstructured":"Walsh TD, Rivera NI, Kaiko R. Oral morphine and respiratory function amongst hospice inpatients with advanced cancer. Support Care Cancer Off J Multinatl Assoc Support Care Cancer. 2003;11:780\u20134.","DOI":"10.1007\/s00520-003-0530-0"},{"key":"2867_CR43","doi-asserted-by":"crossref","unstructured":"Bureau C, Ni\u00e9rat M-C, Decav\u00e8le M, Rivals I, Dangers L, Beurton A, et al. Sensory interventions to relieve dyspnea in critically ill mechanically ventilated patients. Eur Respir J. 2023;2202215.","DOI":"10.1183\/13993003.02215-2022"}],"container-title":["Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-024-02867-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12931-024-02867-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-024-02867-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,16]],"date-time":"2024-07-16T10:06:12Z","timestamp":1721124372000},"score":1,"resource":{"primary":{"URL":"https:\/\/respiratory-research.biomedcentral.com\/articles\/10.1186\/s12931-024-02867-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,16]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["2867"],"URL":"https:\/\/doi.org\/10.1186\/s12931-024-02867-2","relation":{},"ISSN":["1465-993X"],"issn-type":[{"value":"1465-993X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,16]]},"assertion":[{"value":"9 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The trial was approved by the Institutional Review Board (South Mediterranean III Comit\u00e9 de Protection des Personnes on December 5, 2019, no. 19.10.24.60836). All patients or relatives provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Robin Deleris has nothing to disclose. C\u00f4me Bureau has nothing to disclose. Sa\u00efd Lebbah has nothing to disclose. Maxens Decav\u00e8le reports support for attending meetings and\/or travel from Isis medical, outside the submitted work. Martin Dres reports personal fees and grants from Lungpacer unrelated to the work submitted. Julien Mayaux reports support for attending meetings and\/or travel from Gilead, outside the submitted work. Thomas Similowski reports grants from Lungpacer, consulting fees from ADEP Assistance, AstraZeneca France, Chiesi France, KPL consulting, Lungpacer Inc, Novartis France, TEVA France and Vitalaire, outside the submitted work. Agn\u00e8s Dechartres reports grants from the French Ministry of Health. Alexandre Demoule reports grants, personal fees and non-financial support from Philips, personal fees from Baxter, personal fees and non-financial support from Fisher & Paykel, grants from the French Ministry of Health, grants from Assistance Publique \u2013 H\u00f4pitaux de Paris, personal fees from Getinge, grants, personal fees and non-financial support from Respinor, grants, personal fees and non-financial support from Lungpacer, personal fees from Lowenstein and personal fees from Gilead, outside the submitted work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"280"}}